Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Women Exec Ratio 14.7% among TSE Prime Drug Makers, Wholesalers; Astellas Leads the Way at 30%
June 2, 2023
- CSL Behring Launches App to Manage HAE Records
June 2, 2023
- Japan Pharma Market Grows for 2 Years Running with 2.6% Rise in FY2022: IQVIA
June 2, 2023
- Shionogi Shoots for Doubling Revenue to 800 Billion Yen by FY2030
June 2, 2023
- Ferring Japan Recalling Fertility Drug Lutinus after Bacteria Detection
June 2, 2023
- Shionogi to End Crestor Sales, AstraZeneca to Go Solo
June 2, 2023
- Pharma Companies in Japan Raising Retirement Age, Extending Rehiring: Jiho Poll
June 1, 2023
- Nipro Pharma Submits Business Improvement Plan after GMP Issues
June 1, 2023
- AnGes Seeks Full Approval for Gene Therapy Collategene in Japan
June 1, 2023
- Braftovi/Mektovi Filed for Thyroid Cancer in Japan: Ono
June 1, 2023
- Maruho’s Bepio Lotion Hits Japan Pharmacy Shelves
June 1, 2023
- AbbVie Aims to Double Japan Sales to 200 Billion Yen by 2030: Local Chief
May 31, 2023
- Jeremy Grossas to Head Up Merck Biopharma Japan
May 30, 2023
- Nobelpharma Gets EU Nod for Hyftor
May 30, 2023
- Pfizer Japan Files RSV Vaccine for 60 Years of Age and Older
May 29, 2023
- Chugai’s FoundationOne Liquid Wins Approval as Tabrecta CDx
May 29, 2023
- Seikagaku Nets Positive Data in Additional US PIII for Herniated Disk Drug
May 29, 2023
- Hutchmed’s Colorectal Cancer Med Gets FDA’s Priority Review: Takeda
May 29, 2023
- PharmaEssentia’s 1st Product to Hit Japan Market on June 1
May 29, 2023
- Ex-Takeda Exec Motoi Muraki to Take Helm at ViiV Japan
May 26, 2023
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…